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Reduced susceptibility to daptomycin has been reported in patients with infections due to methicillin-
resistant Staphylococcus aureus (MRSA). Although infections with daptomycin-nonsusceptible (DNS) MRSA
are infrequent, optimal therapy of these strains has not been determined. We investigated the killing effects of
novel antibiotic combinations with daptomycin (DAP) against two clinical DNS MRSA isolates (SA-684 and
R6003) in a 72-h in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial
vegetations (SEV). Simulated regimens included DAP at 6 mg/kg every 24 h (q24h) alone or in combination
with trimethoprim-sulfamethoxazole (TMP/SMX) at 160/800 mg q12h, linezolid (LIN) at 600 mg q12h,
cefepime (CEF) at 2 g q12h, and nafcillin (NAF) at 4 g q4h. Bactericidal activity was defined as a >3-log10
CFU/g kill. Differences in CFU/g were evaluated between 4 and 72 h by analysis of variance with the Bonferroni
post hoc test. DAP MICs were 4 and 2 mg/liter for SA-684 and R6003, respectively. In the PK/PD model, DAP
alone was slowly bactericidal, achieving a 3-log10 kill at 24 and 50 h for SA-684 and R6003, respectively. Against
SA-684, DAP plus TMP/SMX, CEF, LIN, or NAF was bactericidal at 4, 4, 8, and 8 h, respectively, and
maintained this activity for the 72-h study duration. DAP plus TMP/SMX or CEF exhibited superior killing
than DAP alone against SA-684 between 4 and 72 h, and overall this was significant (P < 0.05). Against R6003,
DAP plus TMP/SMX was bactericidal (8 h) and superior to DAP alone between 8 and 72 h (P < 0.001). The
unique combination of DAP plus TMP/SMX was the most effective and rapidly bactericidal regimen against the
two isolates tested and may provide a clinical option to treat DNS S. aureus infections.
Daptomycin (DAP) is a concentration-dependent cyclic li-
popeptide antibiotic with activity against Gram-positive organ-
isms that exerts its bactericidal activity by binding to and in-
serting into bacterial membranes, thereby leading to rapid
membrane depolarization and deregulation of several cell
functions, such as DNA, RNA, and protein synthesis (11, 19,
32). Daptomycin susceptibility in Staphylococcus aureus is de-
fined as a MIC of 1 g/ml, and any strains with a MIC of 1
g/ml are referred to as daptomycin nonsusceptible (DNS)
(10). The rate of DNS S. aureus in North America over the last
several years is low (0.01 to 0.1%), with no trend for increasing
MICs reported by several investigators (8, 26, 30, 31). Re-
ported cases of DNS developing during treatment occur mainly
in patients with S. aureus infections such as osteomyelitis, sep-
tic arthritis, or endocarditis and generally occur after vanco-
mycin (VAN) therapy (6, 33). Optimal therapy for these types
of infections involves therapy with bactericidal agents to en-
sure a rapid reduction of the bacterial burden as well as signs
and symptoms of the infection. Unfortunately, commonly used
alternative antistaphylococcal antibiotics, including linezolid
(LIN), tigecycline, trimethoprim/sulfamethazole (TMP/SMX),
clindamycin, and tetracyclines, are typically bacteriostatic
agents. In addition, clinical data on successful treatment of
infections caused by DNS S. aureus are limited to a few case
reports (33). The optimal therapy for the treatment of infec-
tions caused by DNS S. aureus, particularly where a bacteri-
cidal regimen is desired, is therefore currently unknown.
Daptomycin nonsusceptibility in S. aureus does not appear
to be an all-or-nothing phenomenon but instead a series of
incremental changes that increase the MIC and eventually lead
to DNS strains (13, 16). To date, four main genetic changes
have been associated with increased MICs and DNS S. aureus
(13). A single point mutation or overexpression of the mprF
protein, a lysylphosphatidylglycerol synthase, is thought to con-
tribute to DNS by affecting the composition of lysylphosphati-
dylglycerol in the cell membrane (25, 39). Another altered
protein sometimes found in DNS strains is YycG, a histidine
kinase that is one of two components of a response regulator
system responsible for cell membrane metabolism (13). Point
mutations in the proteins RpoB and RpoC, which comprise the
 and  subunit of RNA polymerase, have also been associ-
ated with DNS S. aureus strains (13). There are likely other
genetic changes leading to DNS in S. aureus, as strains exhib-
iting elevated MICs often have only some or occasionally none
of the above-mentioned changes (16, 17, 28). A recent inves-
tigation also suggested that membrane proteins may augment
the bactericidal effect of daptomycin and that alteration or loss
of these proteins may contribute to DNS in S. aureus (18, 25).
Additionally, altered membrane potential, increased mem-
brane fluidity, increased positive membrane surface charge,
increased cell wall thickness, and decreased membrane de-
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polarization have been found in DNS S. aureus strains (16,
25, 34).
Since the development of DNS in S. aureus is due to stepwise
changes, daptomycin appears to retain some activity against
these strains, although at the expense of its rapid bactericidal
activity (27, 29). Daptomycin at simulated doses of 6 mg/kg and
10 mg/kg has been shown to have bactericidal activity in in vitro
pharmacokinetic/pharmacodynamic (PK/PD) models against
some DNS S. aureus strains, although the time to bactericidal
activity was increased and regrowth often occurred (27, 29).
The addition of gentamicin (GEN) or rifampin (RIF) to dap-
tomycin led to (or increased) the bactericidal effect of dapto-
mycin against some of these strains (27). We therefore hypoth-
esized that alternative novel daptomycin combinations may
provide rapid bactericidal activity against DNS S. aureus. The
objective of the study was to evaluate the bactericidal activity
of various daptomycin combinations against clinical DNS S.
aureus strains in an in vitro PK/PD model with simulated en-
docardial vegetations (SEV).
MATERIALS AND METHODS
Bacterial strains. Two clinical DNS methicillin-resistant S. aureus (MRSA)
strains (SA-684 and R6003) exhibiting daptomycin MICs equal to or greater than
2 mg/liter and vancomycin MICs equal to or greater than 1 mg/liter were inves-
tigated in the in vitro SEV PK/PD model over a 72-h period. SA-684 was
recovered from a patient during therapy for tricuspid endocarditis and was
provided by G. W. Kaatz, J. Dingell VA Hospital, Detroit, MI (18). R6003
was isolated from a patient being treated for bacteremia from the Detroit
Medical Center in 2009.
Antimicrobials. TMP/SMX and nafcillin (NAF) were commercially purchased
from Sigma-Aldrich Co. (St. Louis, MO). DAP, LIN, and cefepime (CEF) were
also commercially purchased as the human injectable product. Stock solutions of
each antimicrobial were prepared daily per CLSI recommendations (10).
Media. Mueller-Hinton broth (Difco, Detroit, MI) supplemented with 25
mg/liter calcium and 12.5 mg/liter magnesium (25 SMHB) was used for all in vitro
PK/PD models and MIC testing, except for experiments with DAP and NAF. For
experiments with daptomycin, Mueller-Hinton broth was supplemented with 50
mg/liter calcium for MIC testing and 75 mg/liter calcium for in vitro PK/PD
models, due to the presence of albumin in the SEV (20). For experiments with
nafcillin, 25 SMHB was supplemented with 4% NaCl as recommended by the
CLSI guidelines, to induce expression of penicillin-binding protein 2a (PBP 2a)
(9, 10). Colony counts were determined using tryptic soy agar (TSA; Difco,
Detroit, MI) plates. Development of resistance was evaluated using either Muel-
ler-Hinton agar (MHA; Difco, Detroit, MI) or brain heart infusion agar (BHI;
Difco, Detroit, MI) plates containing the indicated antimicrobial.
Susceptibility testing. MICs of studied antimicrobial agents were determined
in duplicate by broth microdilution at log 106, according to the CLSI guidelines
(10).
In vitro pharmacodynamic model. An in vitro model consisting of a 250-ml
two-compartment glass apparatus with ports, where the SEV were suspended
into the system, was utilized for all simulations. The apparatus was prefilled with
medium, and antibiotics were administered as boluses over a 72-hour time period
into the central compartment via an injection port. The model apparatus was
placed in a 37°C water bath throughout the procedure, and a magnetic stir bar
was placed in the medium for thorough mixing of the drug in the system. Fresh
medium was continuously supplied and removed from the compartment along
with the drug via a peristaltic pump (Masterflex; Cole-Parmer Instrument Com-
pany, Chicago, IL) that was set to simulate the in vivo pharmacokinetic profiles
of the antibiotics. The antibiotic simulated regimens were DAP at 6 mg/kg every
24 h (estimated total peak, 98.6 mg/liter; t1⁄2, 8 h) (4), TMP/SMX at 160/800 mg
every 12 h (peak, 2.4/100 mg/liter; t1⁄2, 10/10 h) (21), LIN at 600 mg every 12 h
(peak, 15.1 mg/liter; t1⁄2, 5 h) (14), CEF at 2 g ever 8 h (peak, 163.9 mg/liter; t1⁄2,
2.5 h) (7), and nafcillin at 2 g every 4 h (peak, 40 mg/liter; t1⁄2, 1 h). Combination
regimens simulated included DAP plus TMP/SMX, DAP plus CEF, DAP plus
LIN, and DAP plus NAF. The elimination rate for each of the combination
models was set for the antibiotic with the shorter half-life, and the antibiotic with
a longer half-life was supplemented into the second chamber at the above-
described dosing intervals (5). All experiments were performed in duplicate to
ensure reproducibility.
SEV. Organism stocks were prepared by inoculating six TSA plates with lawns
for overnight growth at 37°C. Organisms were swabbed from the growth plates
into SMHB. SEV were prepared by mixing 0.05 ml of organism suspension (final
inoculum, 109 CFU/0.5 g), 0.5 ml of human cryoprecipitated antihemolytic factor
from volunteer donors (American Red Cross, Detroit, MI), and 0.025 ml of
human donor platelets (American Red Cross, Detroit, MI). Bovine thrombin
(5,000 units/ml; 0.05 ml) was then added to each Eppendorf tube after insertion
of a sterile monofilament fish line into the mixture. The resultant simulated
vegetations (16) were then introduced into the model apparatus. This meth-
odology results in SEV consisting of approximately 3 to 3.5 g/dl of albumin and
6.8 to 7.4 g/dl of total protein (1).
Pharmacodynamic analysis. Two SEV were removed from each model system
(total of four at each time point) at 0, 4, 8, 24, 32, 48, 56, and 72 h. The SEV were
homogenized and diluted in cold saline to be plated onto TSA plates. For all
samples, antimicrobial carryover was accounted for by serial dilution of the
plated samples. If the anticipated dilution was near the MIC, then vacuum
filtration was also used. When vacuum filtration was used, samples were washed
through a 0.45-m filter with normal saline to remove the antimicrobial agent.
Plates were then incubated at 37°C for 24 h, at which time colony counts were
performed. The total reduction in log10 CFU/g over 72 h was determined by
plotting time-kill curves based on the number of remaining organisms over the
72-h time period. Bactericidal activity (99% kill) was defined as a 3-log10
CFU/g reduction in colony count from the initial inoculum. The time to achieve
a 99.9% bacterial load reduction was determined by linear regression (if r2 was
0.95) or visual inspection of log10 CFU/g.
Pharmacokinetic analysis. Pharmacokinetic samples were obtained through
the injection port of each model (duplicate samples) at 0.5, 1, 2, 4, 8, 24, 32, 48,
56, and 72 h for verification of target antibiotic concentrations. All samples were
then stored at 70°C until analysis. Previously validated bioassays were utilized
for DAP (Micrococcus luteus ATCC 9341; antibiotic assay medium 1; standards
of 150, 75, and 37.5 mg/liter) (2), CEF (Micrococcus luteus ATCC 9341; antibiotic
assay medium 5; standards of 60, 30, and 15 mg/liter) (3), and NAF (Micrococcus
luteus ATCC 9341; Mueller-Hinton agar; standards of 15, 7.5, and 3.125 mg/liter
with a 1:2 dilution of pharmacokinetic samples) (22). Blank 1⁄4-inch disks were
placed on a preswabbed plate of appropriate antibiotic medium and spotted with
10 l of the standard or sample. For TMP we utilized a bioassay (S. aureus
R1867; Mueller-Hinton agar; standards of 40, 20, and 10 mg/liter). Briefly,
1⁄4-inch holes were punched in the preswabbed agar plate and filled with 100 l
of the standard or sample. This assay has a lower limit of detection of 10 mg/liter
and a between-day coefficient of variation (CV) of 7.2%. A separate model was
run at 10 times the targeted concentration to utilize this assay, due to its detec-
tion limits. For SMX we utilized a bioassay (S. aureus R1867; Mueller-Hinton
agar; standards of 500, 250, and 125 mg/liter). Briefly, 1⁄4-inch holes were
punched in the preswabbed agar plate and filled with 50 l of the standard or
sample, which contained 6 mg/liter of trimethoprim. This assay had a between-
day CV of 5.8%. A separate model was run for SMX to evaluate pharmacoki-
netic parameters. Each standard was tested in duplicate. Plates were incubated
for 18 to 24 h at 37°C, after which time the zone sizes were measured using a
protocol reader (Protocol; Microbiology International, Frederick, MD). Lin-
ezolid samples were evaluated using a validated high-performance liquid chro-
matography (HPLC) assay with standards ranging from 0.5 mg/liter to 30 mg/liter
(12, 24, 35). This assay has a CV of 1.1 to 4.4%. The half-lives, areas under the
time-concentration curves (AUCs), AUC/MIC ratios, and peak concentrations
of the antibiotics were determined by the trapezoidal method utilizing PK An-
alyst software (version 1.10; MicroMath Scientific Software, Salt Lake City, UT).
Resistance. Development of resistance was evaluated at multiple time points
for DAP and the antimicrobials that tested susceptible throughout the simulation
at 8, 24, 48, and 72 h. Samples (100 l) from each time point were plated on MH
(for DAP) or BHI plates containing a 3-fold dilution of the drug’s initial MIC.
Plates were then examined for growth after 24 to 48 h of incubation at 35°C.
Statistical analysis. Changes in CFU/g at all time points for the combination
regimen and the most active single-drug regimen were compared with a one-way
analysis of variance and the Bonferroni post hoc test. A P value of 0.05 was
considered significant. All statistical analyses were performed using SPSS Sta-
tistical software (release 18.0; SPSS, Inc., Chicago, IL).
RESULTS
The MIC results for the tested isolates are summarized in
Table 1. The two strains, SA-684 and R6003, displayed DAP
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MICs of 4 and 2 g/ml, respectively. Both isolates displayed a
VAN MIC of 2 g/ml and were susceptible to LIN and TMP/
SMX. Examination of these two strains by vancomycin popu-
lation analysis revealed that SA-684 was negative for the het-
erogenously vancomycin-intermediate S. aureus (hVISA)
phenotype (ratio with Mu3, 0.88) but was heterovariant to
daptomycin, while R6003 was positive for hVISA (ratio with
Mu3, 0.97) and was heterovariant to daptomycin. As expected,
these MRSA isolates were resistant to oxacillin (OXA) and
had CEF MIC values of greater than 32 g/ml.
Observed total peak and t1⁄2 values were within the following
ranges: DAP (peak, 107.74 to 114 mg/liter; t1⁄2, 7.8 to 8.8 h),
CEF (169.17 to 189.02 mg/liter; 3.02 to 3.13 h), NAF (29.17 to
33.67 mg/liter; 1.1 to 1.27 h), TMP (23.35 to 25.5 mg/liter; 8.8
to 9.9 h), SMX (96 mg/liter; 9.8 to 10.4 h), LIN (16.38 to 17.69
mg/liter; 4.3 to 4.4 h).
The quantitative changes in the log10 CFU/g for the 72-h in
vitro SEV models are displayed in Fig. 1a and b and 2a and b
for SA-684 and R6003, respectively. Time-to-bactericidal ac-
tivity (3-log10 kill) for SA-684 was 24 h for DAP, 4 h for DAP
plus TMP/SMX, 4 h for DAP plus CEF, 8 h for DAP plus LIN,
and 8 h for DAP plus NAF. The magnitude of bacterial killing
was greater for DAP plus TMP/SMX and for DAP plus CEF,
which reached the limit of detection by 8 h and maintained a
bacterial density to approximately 2 log10 CFU/g for the re-
mainder of the 72-h experiment. This was in contrast to DAP
plus NAF, which barely maintained bactericidal activity for the
72 h. For R6003, DAP was bactericidal at 50 h, and the only
combination to produce a bactericidal effect was DAP plus
TMP/SMX (8 h). DAP was the most effective single-agent
regimen tested at 72 h. Comparison of DAP alone to the
combination regimens for all time points between 4 and 72 h
revealed that some combinations were significantly more ef-
fective at decreasing the bacterial density. Both DAP plus
TMP/SMX (P  0.05) and DAP plus CEF (P  0.05) were
significantly better than DAP alone between 4 and 72 h for
SA-684. Additionally, DAP plus LIN (P  0.05) was signifi-
cantly better than DAP alone at some of the tested time points,
including 72 h. For R6003, the combination of DAP plus TMP/
SMX was significantly greater than DAP for all time points
from 8 to 72 h. Exposing samples on plates containing antimi-
crobials at threefold the MIC did not reveal development of
resistance during any of the regimens tested.
DISCUSSION
As stated previously, limited data are available regarding
bactericidal treatment options for DNS S. aureus infections. In
the present study, the activities of novel DAP combinations
against two clinical DNS MRSA strains were examined in an in
vitro PK/PD SEV model. Based on our results, the unique
combination of DAP plus TMP/SMX provided the most con-
sistent rapid bactericidal activity and superiority to DAP alone.
DAP plus CEF and DAP plus LIN also showed superior ac-
tivity to DAP alone against one of the tested strains, SA-684,
which was negative for the hVISA phenotype.
Previous PK/PD in vitro model experiments examining the
activity of DAP in combination with other antimicrobial agents
have focused on combinations such as DAP with GEN, RIF, or
arbekacin (ABK) (2, 22, 27, 36). Studies that examined methi-
cillin-susceptible S. aureus, MRSA, and VISA strains found
that in most cases the time to bactericidal activity was de-
creased with the addition of GEN or ABK, although synergy
FIG. 1. (a) Activity of DAP, CEF, and LIN alone and in combina-
tion against SA-684. (b) Activity of DAP, NAF, and TMP/SMX alone
and in combination against SA-684.
TABLE 1. MIC values of antibiotics
Strain
MIC (g/ml)
VAN DAP LIN TMP/SMX CEF OXA
SA-684 2 4 1 0.0625/1.19 32 32
R6003 2 2 1 0.0313/0.59 32 32
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was not always observed, due to the activity of DAP alone (2,
22, 36). One in vitro PK/PD SEV model examined the activity
of DAP at simulated doses of 6 and 10 mg/kg/day alone and in
combination with GEN or RIF against DNS S. aureus strains
from the endocarditis clinical trial (27). These combinations
produced variable results, with bactericidal activities against
only two of the four tested strains for DAP plus GEN and
bactericidal activities against four strains for DAP plus RIF,
but only in combination with DAP at 10 mg/kg/day for three of
the strains; antagonism was demonstrated with one strain.
Time to bactericidal activity was generally greater than 24 h.
To our knowledge, other than the previously mentioned stud-
ies, no other in vitro PK/PD models have examined the activ-
ities of combination regimens against DNS S. aureus strains
and no other in vitro or in vivo studies have evaluated the
potential of combining daptomycin with other anti-MRSA
agents.
The other antimicrobial agents used in this study have been
examined for synergy or enhanced bactericidal activity against
S. aureus in previous in vitro PK/PD models as well. The com-
bination of TMP/SMX plus gemifloxacin displayed both syn-
ergistic and enhanced killing against two community-acquired
MRSA strains in an in vitro PK/PD one-compartment model
(23). Although CEF is not known to have any significant ac-
tivity against MRSA strains when administered alone, previous
studies have demonstrated the activity of CEF against MRSA
when used in combination with other antimicrobial agents. The
combination of CEF and VAN was rapidly bactericidal against
MRSA strains in an in vitro one-compartment model, while the
combination of CEF plus LIN and CEF plus quinupristin-
dalfopristin showed improvement (2-log10 CFU/ml increase
in kill) over the activity of the single agents (3). The combina-
tion of CEF plus GEN or tobramycin demonstrated rapid
bactericidal activity against two clinical MRSA strains when
examined in the same model (15). The addition of CEF to
DAP in this study did not show any additional activity, as DAP
was rapidly and persistently bactericidal alone. LIN in combi-
nation with VAN or CEF led to an improvement in activity
against MRSA strains, while LIN plus GEN did not display
enhanced activity (3, 15, 22).
To our knowledge, the rapid and sustained bactericidal ac-
tivity of DAP plus TMP/SMX obtained in this study is a novel
finding. The activities of CEF and LIN in combination with
other antimicrobials found in the above-mentioned earlier
studies are relatively consistent with the findings of this study.
The combination of DAP plus NAF did not produce any en-
hanced effect in this study. This combination was of interest,
because previous studies showed increased oxacillin suscepti-
bility in the DNS MRSA strains (38). A similar phenomenon
has also been seen in VISA strains, as a recent study found
16% of tested strains (all mecA positive) to be oxacillin sus-
ceptible based on their MIC values (37). The strains in this
study, however, were specifically chosen because they were
MRSA that still tested resistant to oxacillin, and this may
explain the lack of enhanced effect for the combination of
DAP plus NAF. It is possible cefepime displayed synergistic
activity with daptomycin against one of the strains due to
low-level affinity for PBP 2a in MRSA. (15). The combination
of DAP plus TMP/SMX was the only combination that pro-
duced both rapid bactericidal activity and enhanced activity
against both strains, including the hVISA strain R6003.
Limitations of this study include its short duration and use of
only two strains. A previous study with one of the strains
(SA-684) showed that although DAP is eventually bactericidal,
regrowth continues to occur after 72 h, which may be because
the strain is heterovariant to daptomycin (29). Extending the
experiment duration beyond 72 h may have found additional
and prolonged synergy. The two strains utilized in this study
produced different results, likely due to their unique clinical
backgrounds, with DAP plus TMP/SMX being the consistently
most effective regimen. The ability to extrapolate these data to
other DNS S. aureus strains with higher DAP MICs may be
FIG. 2. (a) Activity of DAP, CEF, and LIN alone and in combina-
tion against R6003. (b) Activity of DAP, NAF, and TMP/SMX alone
and in combination against R6003.
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limited, as DAP remained the single most active agent in the
combinations.
In conclusion, the novel combination of DAP plus TMP/
SMX provided rapid bactericidal activity and provides a ther-
apeutic option for treating DNS MRSA infections, especially
when bactericidal activity is desired. Daptomycin in combina-
tion with CEF and LIN also provided enhanced activity. Fur-
ther study with these combinations is warranted.
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